Firat Ileri

Valthos builds next-generation biodefense. Of all AI applications, biotechnology has the highest upside and most catastrophic downside. Heroes at the frontlines of biodefense are working every day to protect the world against the worst case. But the pace of biotech is against them: more powerful methods to design biological systems, with near-universal access, open up an increasing surface area of threats. In this new world, the only way forward is to be faster. So we set out to build the tech stack for biodefense. Our team of computational biologists and software engineers applies frontier AI to identify biological threats and update medical countermeasures in real-time. We are backed by $30M from @OpenAI, @Lux_Capital, @foundersfund and others including @Definition_Cap. We are actively hiring engineers to join in the mission - if that sounds like you, get in touch.

We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: tinyurl.com/545v3bwu Read our feature in @Bloomberg here: tinyurl.com/yj4e8j8f